Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration

Gene Therapy

Volumn 6, Issue 9, 1999, Pages 1565-1573

  Parks, R J ^a,b   Evelegh, C M ^a   Graham, F L ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

Adenovirus; Neutralizing antibody; Serotype; Vectors

Indexed keywords

NEUTRALIZING ANTIBODY; VIRUS DNA; VIRUS VECTOR;

ADENOVIRUS; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; GENE EXPRESSION SYSTEM; GENE THERAPY; GENETIC TRANSDUCTION; HELPER VIRUS; KINETICS; LIVER; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEROTYPE; TRANSGENE; VIRION;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, VIRAL; BETA-GALACTOSIDASE; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HELPER VIRUSES; HUMANS; MICE; MICE, INBRED STRAINS; SEROTYPING; TUMOR CELLS, CULTURED;

ADENOVIRIDAE; ANIMALIA; DNA VIRUSES;

EID: 0032827780     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300995     Document Type: Article

References (74)

1. Hitt MM, Addison CL, Graham FL. Human adenovirus vectors for gene transfer into mammalian cells. Adv Pharmacol 1997; 40: 137-206.
2. Yang Y et al. Cellular immunity to viral antigens limits Eldeleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994; 91: 4407-4411.
3. Yang Y, Wilson JM. Clearance of adenovirus-infected hepatocytes by MHC class I-restricted CD4+ CTLs in vivo. J Immunol 1995; 155: 2564-2570.
4. Yang Y et al. Upregulation of class I major histocompatibility complex antigens by interferon gamma is necessary for T-cell-mediated elimination of recombinant adenovirus-infected hepatocytes in vivo. Proc Natl Acad Sci USA 1995; 92: 7257-7261.
5. Yang Y, Su Q, Wilson JM. Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs. J Virol 1996; 70: 7209-7212.
6. Yang Y et al. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Therapy 1996; 3: 137-144.
7. Dai Y et al. Cellular and humoral immune responses to adenovirual vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci USA 1995; 92: 1401-1405.
8. Gilgenkrantz H et al. Transient expression of genes transferred in vivo into heart using first-generation adenoviral vectors: role of the immune response. Hum Gene Ther 1995; 6: 1265-1274.
9. McCoy RD et al. Pulmonary inflammation induced by incomplete or inactivated adenoviral particles. Hum Gene Ther 1995; 6: 1553-1560.
10. Morral N et al. Immune responses to reporter proteinsa nd high viral dose limit duration of expressiion with adenoviral vectors: comparison of E2a wild type and E2a deleted vectors. Hum Gene Ther 1997; 8: 1275-1286.
11. Christ M et al. Gene therapy with recombinant adenovirus vectors: evaluation of the host immune response. Immunol Lett 1997; 57: 19-25.
12. Kafri T et al. Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: implications for gene therapy. Proc Natl Acad Sci USA 1998; 95: 11377-11382.
13. van Ginkel FW et al. Adenoviral gene delivery elicits distinct pulmonary-associated T helper cell responses to the vector and to its transgene. J Immunol 1997; 159: 685-693.
14. Dong JY et al. Systematic analysis of repeated gene delivery into animal lungs with a recombinant adenovirus vector. Hum Gene Ther 1996; 7: 319-331.
15. Kaplan JM et al. Humoral and cellular immune responses of nonhuman primates to long-term repeated lung exposure to Ad2/CFTR-2. Gene Therapy 1996; 3: 117-127.
16. St George JA et al. Biological response of nonhuman primates to long-term repeated lung exposure to Ad2/CFTR-2. Gene Therapy 1996; 3: 103-116.
17. Schulick AH et al. Established immunity precludes adenovirus-mediated gene transfer in rat carotid arteries. Potential for immunosuppression and vector engineering to overcome barriers of immunity. J Clin Invest 1997; 99: 209-219.
18. Lee MG et al. The constitutive expression of the immunomodulatory gp19k protein in E1-, E3- adenoviral vectors strongly reduces the host cytotoxic T cell response against the vector. Gene Therapy 1995; 2: 256-262.
19. Poller W et al. Stabilization of transgene expression by incorporation of E3 region genes into an adenoviral factor IX vector and by transient anti-CD4 treatment of the host. Gene Therapy 1996; 3: 521-530.
20. Bruder JT et al. Expressionof gp19K increases the persistence of transgene expression from an adenovirus vector in the mouse lung and liver. J Virol 1997; 71: 7623-7628.
21. Ilan Y et al. Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humorla and cellular immune responses and permits long-term gene expression. Proc Natl Acad Sci USA 1997; 94: 2587-2592.
22. Schowalter DB et al. Heterologous expression of adenovirus E3-gp19K in an Ela-deleted adenovirus vector inhibits MHC I expression in vitro, but does not prolong transgene expresssion in vivo. Gene Therapy 1997; 4: 351-360.
23. Engelhardt JF et al. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci USA 1994; 91: 6196-6200.
24. Yang Y et al. Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrossis. Nat Genet 1994; 7: 362-369.
25. Goldman MJ et al. Transfer of the CFTR gene to the lung of nonhuman primates with E1-deleted, E2a-defective recombinant adenoviruses: a preclinical toxicology study. Hum Gene Ther 1995; 6: 839-851.
26. Gao GP, Yang Y, Wilson JM. Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy. J Virol 1996; 70: 8934-8943.
27. Dedieu JF et al. Long-term gene delivery into the livers of immunocompetent mice with E1/E4-defective adenoviruses. J Virol 1997; 71: 4626-4637.
28. Wang Q et al. Persistent transgene expression in mouse liver following in vivo gene transfer with a delta E1/delta E4 adenovirus vector. Gene Therapy 1997; 4: 393-400.
29. Amalfitano A et al. Production and characterization of improved adenovirus vectors with El, E2b, and E3 genes deleted. J Virol 1998; 72: 926-933.
30. Fang B et al. Lack of persistence of E1- recombinant adenoviral vectors containing a temperature-sensitive E2A mutation in immunocompetent mice and hemophilia B dogs. Gene Therapy 1996; 3: 217-222.
31. Lusky M et al. In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1 /E2A, or E1 /E4 deleted. J Virol 1998; 72: 2022-2032.
32. Mitani K et al. Rescue, propagation, and partial purification of a helper virus-dependent adenovirus vector. Prof Natl Acad Sci USA 1995; 92: 3854-3858.
33. Fisher KJ et al. Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis. Virology 1996; 217: 11-22.
34. Haecker SE et al. In vivo expression of full-length human dystrophin from adenoviral vectors deleted of all viral genes. Hum Gene Ther 1996; 7: 1907-1914.
35. Kochanek S et al. A new adenoviral vector: replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. Proc Natl Acad Sci USA 1996; 93: 5731-5736.
36. Kumar-Singh R, Chamberlain JS. Encapsidated adenovirus minichromosomes allow delivery and expression of a 14 kb dystrophin cDNA to muscle cellss. Hum Mol Genet 1996; 5: 913-921.
37. Lieber A et al. Recombinant adenoviruses with large deleteions generated by Cre-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo. J Virol 1996; 70: 8944-8960.
38. Hardy S et al. Construction of adenovirus vectors through Crelox recombinations. J Virol 1997; 71: 1842-1849.
39. Parks RJ et al. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci USA 1996; 93; 13565-13570.
40. Chen HH et al. Persistence in muscle of an adenoviral vector that lacks all viral genes. Proc Natl Acad Sci USA 1997; 94: 1645-1650.
41. Morsy MA et al. An adenoviral vector deleted for all viral coding sequencces results in enhanced safety and extended expression of a leptin transgene. Proc Natl Acad Sci USA 1998; 95: 7866-7871.
42. Schiedner G et al. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat Genet 1998; 18: 180-183.
43. Morral N et al. High doses of a helper-dependent adenoviral vector yield supraphysiological levels of alphal-antitrypsin with negligible toxicity. Hum Gene Ther 1998; 9: 2709-2716.
44. Vilquin JT et al. FK506 immunosuppression to control the immune reactions triggered by first-generation adenovirus-mediated gene transfer. Hum Gene Ther 1995; 6: 1391-1401.
45. Jooss K, Yang Y, Wilson JM. Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung. Hum Gene Ther 1996; 7: 1555-1566.
46. Kass-Eisler A et al. Circumventing the immune response to adenovirus-mediated gene therapy. Gene Therapy 1996; 3: 154-162.
47. Kolls JK et al. Use of transient CD4 lymphocyte depletion to prolong transgene expression of E1-deleted adenoviral vectors. Hum Gene Ther 1996; 7: 489-497.
48. Lochmuller H et al. Transient immunosuppression by FK506 permits a sustained high-level dystrophin expression after adenovirus-mediated dystrophin minigene transfer to skeletal muscles of adult dystrophic (mdx) mice. Gene Therapy 1996; 3: 706-716.
49. Sawchuk SJ et al. Anti-T cell receptor monoclonal antibody prolongs transgene expression following adenovirus-mediated in vivo gene transfer to mouse synovium. Hum Gene Ther 1996; 7: 499-506.
50. Smith TA et al. Transient immunosuppresion permits successful repetitive intravenous administration of an adenovirus vector. Gene Therapy 1996; 3: 496-502.
51. Yang Y, Greenough K, Wilson JM. Transient immune blockade prevents formation of neutralizing antibody to recombinant adenovirus and allows repeated gene transfer to mouse liver. Gene Therapy 1996; 3: 412-420.
52. Zepeda M, Wilson JM. Neonatal cotton rats do not exhibit dstructive immune responses to adenoviral vectors. Gene Therapy 1996; 3: 973-979.
53. Kaplan JM, Smith AE. Transient immunosuppression with deoxyspergualin improves longevity of transgene expression and ability to readminister adenoviral vector to the mouse lung. Hum Gene Ther 1997; 8: 1095-1104.
54. Kuzmin AI, Finegold MJ, Eisensmith RC. Macrophage depletion increasess the safety, efficacy and persistence of adenovirus-mediated gene transfer in vivo. Gene Therapy 1997; 4: 309-316.
55. Lieber A et al. The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. J Virol 1997; 71: 8798-8807.
56. Scaria A et al. Antibody to CD40 ligand inhibits both humoral and cellular immune responses to adenoviral vectors and facilitates repeated administration to mouse airway. Gene Therapy 1997; 4: 611-617.
57. Wolff G et al. Enhancement of in vivo adenovirus-mediated gene transfer and expresssion by prior depletion of tissue macrophages in the target organ. J Virol 1997; 71: 624-629.
58. Zsengeller ZK et al. Anti-T cell receptor antibody prolongs transgene expression and reduces lung inflammation after adenovirus-mediated gene transfer. Hum Gene Ther 1997; 8: 935-941.
59. Mastrangeli A et al. 'Sero-switch' adenovirus-mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype. Hum Gene Ther 1996; 7: 79-87.
60. Mack CA et al. Circumvention of anti-adenovirus neutralizing immunity by administration of an adenoviral vector of an alternate serotype. Hum Gene Ther 1997; 8: 99-109.
61. Roy S et al. Circumvention of immunity to the adenovirus major coat protein hexon. J Virol 1998; 72: 6875-6879.
62. Smith CA et al. Extensive cross-reactivity of adenovirus-specific cytotoxic T cells. Hum Gene Ther 1998; 9: 1419-1427.
63. Chen L, Anton M, Graham FL. Production and characterization of human 293 cell lines expressing the site-specific recombinase Cre. Somat Cell Mol Genet 1996; 22: 477-488.
64. Gahery-Segard H et al. Immune response to recombinant capsid proteins of adenovirus in humans: antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity. J Virol 1998; 72: 2388-2397.
65. Wohlfart C. Neutralization of adenoviruses: kinetics, stoichiometry, and mechanisms. J Virol 1988; 62: 2321-2328.
66. Bett AJ, prevec L, Graham FL. Packaging capacity and stability of human adenovirus type 5 vectors. J Virol 1993; 67: 5911-5921.
67. Parks RJ, Graham FL. A helper-dependent system for adenovirus vector production helps define a lower limit for efficient DNA packaging. J Virol 1997; 71: 3293-3298.
68. Parks RJ et al. Effect of stuffer DNA and viral protein coding sequences on transgene expression from first generation and helper-dependent adenoviral vectors 1999 (submitted).
69. Michou AI et al. Adenovirus-mediated gene transfer: influence of transgene, mouse strain and type of immune response on persistence of transgene expression. Gene Therapy 1997; 4: 473-482.
70. Tripathy SK et al. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nature Meet 1996; 2: 545-550.
71. Graham FL et al. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gene Virol 1997; 36: 59-74.
72. Hitt M et al. Techniques for human adenovirus vector construction and characterization. Meth Mol Genet 1995; 7: 13-30.
73. Bett AJ. Construction and characterization of recombinant adenovirus type 5 vectors. Biology. McMaster: Hamilton, 1995.
74. Addison CL et al. Comparison of the human versus murine cytomegalovirus immediate early gene promoters for transgene expression by adenoviral vectors. J Gen Virol 1997; 78: 1653-1661.